Entera Bio (ENTX) investor relations material

Company overview and business model

• Clinical-stage company developing first-in-class oral peptide therapies for chronic conditions, leveraging the proprietary N-Tab® platform to enable oral delivery of large hydrophilic peptides for diseases such as osteoporosis, hypoparathyroidism, obesity, and short bowel syndrome.

• Lead product EB613 is an oral PTH (1-34) tablet for osteoporosis, aiming to provide an alternative to injectable anabolic therapies and expand access to earlier-stage patients.

• Pipeline includes EB612 (oral PTH for hypoparathyroidism), EB618 (oral GLP-1/Glucagon for obesity/metabolic disorders), and an oral GLP-2 program for short bowel syndrome.

Financial performance and metrics

• Raised approximately $275 million in a private placement in July 2026, selling 134,803,910 ordinary shares (or pre-funded warrants) at $2.04 per share.

• Financial statements incorporated by reference indicate a history of operating losses and a going concern explanatory paragraph from auditors.

Use of proceeds and capital allocation

• Net proceeds from the private placement are allocated to support the initiation of the Phase 3 registrational study of EB613 in postmenopausal women with osteoporosis and for general working capital and corporate purposes.

• No proceeds from the resale of shares by selling shareholders; company bears registration-related fees and expenses.